CONFERENCE ON MONOCLONAL ANTIBODIES

在首次描述单克隆抗体的15年后， 正在看到它们作为药物成功地应用于治疗各种 疾病 蛋白质化学的见解和技术， 分子生物学正在对改进设计产生重大影响， 这些代理人。 最近的临床试验结果已经确定了新的 这些问题正在实验室中迅速解决， 新的解决方案。 因此，在这个关键时刻，迫切需要 将基础和临床科学家以及个人 参与流程设计和法规事务，以设计策略 为未来 沿着这些思路，本次会议将 解决结合位点，效应器机制， 表面受体分子，免疫结合物，蛋白质设计，临床 试验、动物模型和其他影响这些策略的问题。

Fifteen years after the first description of monoclonal antibodies, we are seeing their successful application as drugs to treat a variety of diseases. The insights and technologies of protein chemistry and molecular biology are having a significant impact on improved design of these agents. Results of recent clinical trials have identified new problems which are being rapidly addressed in the laboratory to provide new solutions. Therefore, at this juncture, there is a critical need to bring together basic and clinical scientists as well as individuals involved in process design and regulatory affairs to design strategies for the future. Along these lines, sessions at this conference will address issues in the areas of binding sites, effector mechanisms, surface receptor molecules, immunoconjugates, protein design, clinical trials, animal models, and other issues that impact on these strategies.